Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  acetylsalicylic acid
Find trials that include:  Any drugs shown
Results 1-12 of 12 for your search:
Start Over
PEG-Interferon Alfa-2a or Hydroxyurea in Treating Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MPD-RC 112, NCI-2012-00269, NCT01259856
Enoxaparin or Acetylsalicylic Acid in Preventing Blood Clots in Patients with Cancer and Stroke
Phase: Phase II, Phase I
Type: Supportive care
Age: 18 to 85
Trial IDs: 12-264, NCI-2013-00104, NCT01763606
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Prevention
Age: 40 to 120
Trial IDs: MC054A, NCI-2009-01192, 09-001758, NCT01647126, R01-CA-113681, NCT00983580
PEG-interferon Alfa-2a in Treating Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MPD-RC 111, NCI-2012-00268, 111, NCT01259817
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RV-MM-PI-0345, NCI-2014-01208, NCT01380106
Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: 1300000502, NCI-2014-01006, HHSN2612012000311, N01-CN-2012-00031, UAZ2013-01-01, NCT02123849
Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: UAZ2013-02-01, NCI-2015-00061, 1403269898, HHSN2612012000311, NCT02348203
Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients with Subsolid Lung Nodules
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 50 and over
Trial IDs: 2013-0732, NCI-2014-01311, 2013-004862-32, HHSN261201200034I, IEO 833/13F, IEO 833/13F (IEO37), MDACC-2013-0732, N01-CN-2012-00034, NCT02135497, MDA2013-01-01, NCT02169271
Bortezomib-Based Induction Therapy in Treating Patients With Previously Untreated Multiple Myeloma Undergoing Stem Cell Transplant
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: BMT1020, NCI-2010-02174, NCT01215344
COX2 Inhibition on Biomarker Levels in Serum Samples from Obese Participants
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CTRC 13-0041, NCI-2013-01946, 13-0041, HSC20130426H, NCT02062255
Aspirin with or without Simvastatin in Preventing Cancer-Associated Blood Clots in Patients with Solid Tumors
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: CASE8Y14, NCI-2014-02356, NCT02285738
Aspirin in Preventing Colorectal Cancer in Patients Who Have Undergone Colonoscopy and Adenoma Removal
Phase: No phase specified
Type: Prevention
Age: 18 to 80
Trial IDs: 14-496, NCI-2015-00626, NCT02394769
Start Over